NasdaqGS:TXG

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$20.1b

Last Updated

2021/07/24 00:40 UTC

Data Sources

Company Financials +

Executive Summary

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. More Details


Snowflake Analysis

High growth potential with excellent balance sheet.


Similar Companies

Share Price & News

How has 10x Genomics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TXG is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: TXG's weekly volatility (9%) has been stable over the past year.


Market Performance


7 Day Return

7.2%

TXG

3.3%

US Life Sciences

2.0%

US Market


1 Year Return

93.8%

TXG

45.9%

US Life Sciences

39.1%

US Market

Return vs Industry: TXG exceeded the US Life Sciences industry which returned 41.9% over the past year.

Return vs Market: TXG exceeded the US Market which returned 36.9% over the past year.


Shareholder returns

TXGIndustryMarket
7 Day7.2%3.3%2.0%
30 Day-8.9%4.8%2.3%
90 Day-5.4%8.0%3.5%
1 Year93.8%93.8%46.1%45.9%41.3%39.1%
3 Yearn/a120.4%119.3%64.0%53.8%
5 Yearn/a224.7%220.8%123.8%99.0%

Long-Term Price Volatility Vs. Market

How volatile is 10x Genomics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is 10x Genomics undervalued compared to its fair value and its price relative to the market?

26.72x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: TXG ($183.47) is trading above our estimate of fair value ($28.07)

Significantly Below Fair Value: TXG is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: TXG is unprofitable, so we can't compare its PE Ratio to the US Life Sciences industry average.

PE vs Market: TXG is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TXG's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TXG is overvalued based on its PB Ratio (26.7x) compared to the US Life Sciences industry average (5.8x).


Future Growth

How is 10x Genomics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

56.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TXG is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: TXG is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: TXG's is expected to become profitable in the next 3 years.

Revenue vs Market: TXG's revenue (24.9% per year) is forecast to grow faster than the US market (9.3% per year).

High Growth Revenue: TXG's revenue (24.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TXG is forecast to be unprofitable in 3 years.


Past Performance

How has 10x Genomics performed over the past 5 years?

-77.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TXG is currently unprofitable.

Growing Profit Margin: TXG is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TXG is unprofitable, and losses have increased over the past 5 years at a rate of 77.4% per year.

Accelerating Growth: Unable to compare TXG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TXG is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (34.8%).


Return on Equity

High ROE: TXG has a negative Return on Equity (-70.85%), as it is currently unprofitable.


Financial Health

How is 10x Genomics's financial position?


Financial Position Analysis

Short Term Liabilities: TXG's short term assets ($745.7M) exceed its short term liabilities ($120.5M).

Long Term Liabilities: TXG's short term assets ($745.7M) exceed its long term liabilities ($81.0M).


Debt to Equity History and Analysis

Debt Level: TXG is debt free.

Reducing Debt: TXG had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TXG has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if TXG has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is 10x Genomics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TXG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TXG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TXG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TXG's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TXG's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.6yrs

Average management tenure


CEO

Serge Saxonov (44 yo)

9yrs

Tenure

US$10,882,717

Compensation

Dr. Serge Saxonov, Ph.D, Co-Founded 10X Genomics, Inc. and has been its Chief Executive Officer and Director since July 2012. Prior to 10x Genomics, Dr. Saxonov was Vice President of Applications at Quanta...


CEO Compensation Analysis

Compensation vs Market: Serge's total compensation ($USD10.88M) is about average for companies of similar size in the US market ($USD11.26M).

Compensation vs Earnings: Serge's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: TXG's management team is considered experienced (3.6 years average tenure).


Board Members

Experienced Board: TXG's board of directors are considered experienced (5.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: TXG insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.6%.


Top Shareholders

Company Information

10x Genomics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: 10x Genomics, Inc.
  • Ticker: TXG
  • Exchange: NasdaqGS
  • Founded: 2012
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$20.145b
  • Shares outstanding: 109.80m
  • Website: https://www.10xgenomics.com

Number of Employees


Location

  • 10x Genomics, Inc.
  • 6230 Stoneridge Mall Road
  • Pleasanton
  • California
  • 94588
  • United States

Listings


Biography

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, a...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/07/24 00:40
End of Day Share Price2021/07/23 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.